1. Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis

   • Hyun Jin Song
   • Hyun-Ju Seo
   • Heejeong Son

   Review 15 August 2016 Pages: 1289 - 1301

   

2. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

   • Yanli Zhuang
   • Cesar Calderon
   • Zhenhua Xu

   Clinical Trial 11 August 2016 Pages: 1303 - 1310

   

3. Brain natriuretic peptide for prevention of contrast-inducednephropathy: a meta-analysis of randomized controlled trials

   • Xue-biao Wei
   • Lei Jiang
   • Yuan-hui Liu

   Pharmacodynamics 01 October 2016 Pages: 1311 - 1318

   

4. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland

   • Ewa Stawowczyk
   • Paweł Kawalec
   • Andrzej Pilc

   Pharmacoeconomics Open access 06 August 2016 Pages: 1319 - 1325

   

5. Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese

   • Wu-Tao Zeng
   • Qing Xu
   • Zhi-Sheng Yang

   Pharmacogenetics 04 August 2016 Pages: 1327 - 1334

6. Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson’s patients

   • M Ferrari
   • C Comi
   • M Cosentino

   Pharmacogenetics 06 August 2016 Pages: 1335 - 1341

   

7. Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies

   • Joannes A. A. Reijers
   • T. van Donge
   • J. Stevens

   Pharmacokinetics and Disposition Open access 11 August 2016 Pages: 1343 - 1352

   

8. Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs

   • Yohei Koya
   • Shinya Uchida
   • Tsutomu Kotegawa

   Pharmacokinetics and Disposition Open access 05 August 2016 Pages: 1353 - 1361

   

9. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction

   • Mari Fihlman
   • Tuija Hemmilä
   • Teijo I. Saari

   Pharmacokinetics and Disposition 10 August 2016 Pages: 1363 - 1371

   

10. Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia

    • Naïm Bouazza
    • Zoubir Djerada
    • Michel Polak

    Pharmacokinetics and Disposition 25 August 2016 Pages: 1373 - 1379

    

11. Adherence to antidepressants among women and men described with trajectory models: a Swedish longitudinal study

    • Ann-Charlotte Mårdby
    • Linus Schiöler
    • Anna K. Jönsson

    Pharmacoepidemiology and Prescription 03 August 2016 Pages: 1381 - 1389

    

12. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate

    • Rehana Jamani
    • Esther K. Lee
    • Urban Emmenegger

    Pharmacoepidemiology and Prescription 25 August 2016 Pages: 1391 - 1399

    

13. Quantifying behavioural determinants relating to health professional reporting of medication errors: a cross-sectional survey using the Theoretical Domains Framework

    • Mai Alqubaisi
    • Antonella Tonna
    • Derek Stewart

    Pharmacoepidemiology and Prescription 01 September 2016 Pages: 1401 - 1411

    

14. Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein

    • B. Clarivet
    • P. Robin
    • J. L. Faillie

    Letter to the Editor 26 July 2016 Pages: 1413 - 1414

15. Cetrimide-induced oral mucositis: an unusual adverse drug reaction

    • Giulio Fortuna
    • Enrico Cerchione
    • Marianna Di Lorenzo

    Letter to the Editor 09 August 2016 Pages: 1415 - 1416